RU2007144195A - Способ лечения множественной миеломы с использованием 17-aag или 17-ag или пролекарства любого из них - Google Patents
Способ лечения множественной миеломы с использованием 17-aag или 17-ag или пролекарства любого из них Download PDFInfo
- Publication number
- RU2007144195A RU2007144195A RU2007144195/14A RU2007144195A RU2007144195A RU 2007144195 A RU2007144195 A RU 2007144195A RU 2007144195/14 A RU2007144195/14 A RU 2007144195/14A RU 2007144195 A RU2007144195 A RU 2007144195A RU 2007144195 A RU2007144195 A RU 2007144195A
- Authority
- RU
- Russia
- Prior art keywords
- aag
- dose
- administered
- specified
- max
- Prior art date
Links
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 title claims abstract 52
- 238000000034 method Methods 0.000 title claims abstract 49
- 206010035226 Plasma cell myeloma Diseases 0.000 title claims abstract 5
- 208000034578 Multiple myelomas Diseases 0.000 title claims abstract 3
- 229950007866 tanespimycin Drugs 0.000 title 1
- XYFFWTYOFPSZRM-NBTLBREFSA-N [(3r,5r,6s,7r,8e,10r,11r,12z,14e)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate Chemical compound N1C(=O)\C(C)=C\C=C/[C@@H](OC)[C@H](OC(N)=O)\C(C)=C\[C@@H](C)[C@H](O)[C@H](OC)C[C@H](C)CC2=C(N)C(=O)C=C1C2=O XYFFWTYOFPSZRM-NBTLBREFSA-N 0.000 claims abstract 36
- 239000000651 prodrug Substances 0.000 claims abstract 24
- 229940002612 prodrug Drugs 0.000 claims abstract 24
- 239000003085 diluting agent Substances 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims abstract 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 230000001225 therapeutic effect Effects 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims 4
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims 2
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims 2
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 210000005087 mononuclear cell Anatomy 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67644905P | 2005-04-29 | 2005-04-29 | |
| US60/676,449 | 2005-04-29 | ||
| US68094405P | 2005-05-12 | 2005-05-12 | |
| US60/680,944 | 2005-05-12 | ||
| US72170705P | 2005-09-28 | 2005-09-28 | |
| US60/721,707 | 2005-09-28 | ||
| US74920005P | 2005-12-09 | 2005-12-09 | |
| US60/749,200 | 2005-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007144195A true RU2007144195A (ru) | 2009-06-10 |
Family
ID=37308498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007144195/14A RU2007144195A (ru) | 2005-04-29 | 2006-04-26 | Способ лечения множественной миеломы с использованием 17-aag или 17-ag или пролекарства любого из них |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7691392B2 (enExample) |
| EP (1) | EP1874296A4 (enExample) |
| JP (1) | JP2008539265A (enExample) |
| KR (1) | KR20080000682A (enExample) |
| CN (1) | CN101175489A (enExample) |
| AU (1) | AU2006242540A1 (enExample) |
| BR (1) | BRPI0610411A2 (enExample) |
| CA (1) | CA2604473A1 (enExample) |
| IL (1) | IL186292A0 (enExample) |
| MX (1) | MX2007013494A (enExample) |
| RU (1) | RU2007144195A (enExample) |
| WO (1) | WO2006118953A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090197852A9 (en) * | 2001-08-06 | 2009-08-06 | Johnson Robert G Jr | Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor |
| PE20081506A1 (es) * | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| CN110917190B (zh) * | 2019-11-29 | 2022-12-23 | 中国人民解放军军事科学院军事医学研究院 | 一种抑制阿片类镇痛药物不良反应的制剂及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4261989A (en) * | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| ATE194767T1 (de) * | 1992-03-23 | 2000-08-15 | Univ Georgetown | In liposomen verkapseltes taxol und verwendungsverfahren |
| US5387584A (en) * | 1993-04-07 | 1995-02-07 | Pfizer Inc. | Bicyclic ansamycins |
| WO1994026254A1 (en) | 1993-05-17 | 1994-11-24 | The Liposome Company, Inc. | Incorporation of taxol into liposomes and gels |
| US5415869A (en) * | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
| US5932566A (en) * | 1994-06-16 | 1999-08-03 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
| AU3415295A (en) * | 1994-09-22 | 1996-04-09 | Glenayre Electronics, Inc | Synchronized paging system |
| US5662883A (en) * | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5534270A (en) * | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US6682758B1 (en) * | 1998-12-22 | 2004-01-27 | The United States Of America As Represented By The Department Of Health And Human Services | Water-insoluble drug delivery system |
| WO2000071163A1 (en) | 1999-05-24 | 2000-11-30 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| GB9918429D0 (en) | 1999-08-04 | 1999-10-06 | Novartis Ag | Organic compounds |
| TW200408407A (en) * | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
| CA2481683A1 (en) | 2002-04-10 | 2003-10-23 | Conforma Therapeutics Corporation | Ansamycin formulations and methods for producing and using same |
| WO2004000229A2 (en) * | 2002-06-24 | 2003-12-31 | Research Development Foundation | Treatment of human multiple myeloma by curcumin |
| JP2006514994A (ja) | 2003-03-13 | 2006-05-18 | コンフォーマ・セラピューティクス・コーポレイション | 長鎖および中鎖トリグリセリドを有する医薬製剤 |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| US7282493B2 (en) * | 2003-12-23 | 2007-10-16 | Infinity Pharmaceuticals, Inc. | Analogs of benzoquinone-containing ansamycins and methods of use thereof |
| US20050256097A1 (en) * | 2004-05-11 | 2005-11-17 | Kosan Biosciences, Inc. | Pharmaceutical solution formulations containing 17-AAG |
| WO2005115431A2 (en) | 2004-05-24 | 2005-12-08 | Adonia Papathanassiu | Methods for inhibiting proteasome and heat shock protein 90 |
| WO2006034147A2 (en) | 2004-09-16 | 2006-03-30 | Abraxis Bioscience, Inc. | Compositions and methods for the preparation and administration of poorly water soluble drugs |
| US20060067953A1 (en) * | 2004-09-29 | 2006-03-30 | Conforma Therapeutics Corporation | Oral pharmaceutical formulations and methods for producing and using same |
| JP2008531708A (ja) | 2005-02-28 | 2008-08-14 | コーザン バイオサイエンシス インコーポレイテッド | １７−アリルアミノ−１７−デメトキシゲルダナマイシンを含有する医薬製剤 |
| CA2601706C (en) * | 2005-03-22 | 2016-09-20 | Dana-Farber Cancer Institute, Inc. | Treatment of protein degradation disorders |
| EP1874297A4 (en) * | 2005-04-29 | 2009-04-22 | Kosan Biosciences Inc | METHOD OF TREATING MULTIPLE MYELOMES USING 17AGENE OR 17-AG OR A PRODRUG OR ALL IN COMBINATION WITH A PROTEASOMIC INHIBITOR |
-
2006
- 2006-04-26 CN CNA2006800140087A patent/CN101175489A/zh active Pending
- 2006-04-26 JP JP2008509123A patent/JP2008539265A/ja not_active Abandoned
- 2006-04-26 RU RU2007144195/14A patent/RU2007144195A/ru not_active Application Discontinuation
- 2006-04-26 WO PCT/US2006/016043 patent/WO2006118953A2/en not_active Ceased
- 2006-04-26 US US11/412,298 patent/US7691392B2/en not_active Expired - Fee Related
- 2006-04-26 AU AU2006242540A patent/AU2006242540A1/en not_active Abandoned
- 2006-04-26 MX MX2007013494A patent/MX2007013494A/es not_active Application Discontinuation
- 2006-04-26 EP EP06751653A patent/EP1874296A4/en not_active Withdrawn
- 2006-04-26 KR KR1020077027686A patent/KR20080000682A/ko not_active Withdrawn
- 2006-04-26 CA CA002604473A patent/CA2604473A1/en not_active Abandoned
- 2006-04-26 BR BRPI0610411-8A patent/BRPI0610411A2/pt not_active IP Right Cessation
-
2007
- 2007-09-25 IL IL186292A patent/IL186292A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1874296A2 (en) | 2008-01-09 |
| IL186292A0 (en) | 2008-08-07 |
| MX2007013494A (es) | 2008-01-24 |
| WO2006118953A2 (en) | 2006-11-09 |
| WO2006118953A3 (en) | 2007-12-06 |
| JP2008539265A (ja) | 2008-11-13 |
| US7691392B2 (en) | 2010-04-06 |
| CN101175489A (zh) | 2008-05-07 |
| KR20080000682A (ko) | 2008-01-02 |
| BRPI0610411A2 (pt) | 2010-06-22 |
| EP1874296A4 (en) | 2010-06-30 |
| AU2006242540A1 (en) | 2006-11-09 |
| US20060252739A1 (en) | 2006-11-09 |
| CA2604473A1 (en) | 2006-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL178745A (en) | Use of 4- (amino) -2 (2, 6-dioxo (3-piperidyl)) -isoindoline -1, 3-discussion of preparation of a medical vaccine for the treatment of myeloma | |
| JP2014515373A5 (enExample) | ||
| RU2012106620A (ru) | Комбинации и способы введения терапевтических средств и комбинированной терапии | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| RU94045155A (ru) | Способы ингибирования болезни альцгеймера | |
| RU2008142899A (ru) | Композиции далбаванцина для лечения бактериальных инфекций | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2018507243A5 (enExample) | ||
| CA2459470A1 (en) | Pharmaceutical composition comprising gabapentin or an analogue thereof and an .alpha.-aminoamide and its analgesic use | |
| RU2003125274A (ru) | Применение флумазенила в производстве лекарства для лечения алкогольной зависимости | |
| IL320562A (en) | Cancer treatment methods | |
| AU2018282104A1 (en) | Use of vibegron to treat overactive bladder | |
| CA2435921A1 (en) | Method of cancer therapy | |
| JP2016505050A5 (enExample) | ||
| RU2007144195A (ru) | Способ лечения множественной миеломы с использованием 17-aag или 17-ag или пролекарства любого из них | |
| PL1656131T3 (pl) | Zastosowanie betainy w leczeniu chromania przestankowego | |
| MX2021014944A (es) | Metodos para tratar cancer usando inhibidores de prmt5. | |
| MX2024006270A (es) | Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| MX2024008330A (es) | Combinacion de obicetrapib e inhibidor de sglt2 | |
| JP2008539265A5 (enExample) | ||
| RU2007144204A (ru) | Способ лечения множественной миеломы с использованием 17-aag или 17-ag или пролекарства любого из них в сочетании с ингибитором протеасомы | |
| JPWO2022053990A5 (enExample) | ||
| NZ781127A (en) | Mirikizumab for use in a method of treating crohn’s disease | |
| EA202190724A1 (ru) | Препарат на основе кетамина для лечения депрессий путём ингаляций | |
| RU2013124994A (ru) | КОМБИНАЦИЯ БЕВАЦИЗУМАБА И 2,2-ДИМЕТИЛ-N-((S)-6-ОКСО-6,7-ДИГИДРО-5Н-ДИБЕНЗО[b,d]АЗЕПИН-7-ИЛ)-N'-(2,2,3,3,3-ПЕНТАФТОР-ПРОПИЛ)-МАЛОНАМИДА ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100901 |